Medexus Pharmaceuticals Inc.
MDP.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 120.34% | -3,443.75% | 125.40% | -161.05% | 193.31% |
| Total Depreciation and Amortization | -1.75% | 1.32% | -0.16% | 0.08% | -0.41% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -66.55% | 116.35% | -2.25% | 281.36% | 275.66% |
| Change in Net Operating Assets | -691.42% | -79.10% | 1,426.55% | -150.00% | -6.30% |
| Cash from Operations | -119.20% | -51.64% | 134.67% | -14.85% | 72.19% |
| Capital Expenditure | -633.33% | 84.21% | -171.43% | 94.40% | -135.85% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 7.32% | -17.44% | 75.30% | -346.61% | 81.64% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 73.33% | -50.00% | -- | -- | -- |
| Cash from Investing | 69.11% | -47.09% | -227.85% | 29.30% | -13.48% |
| Total Debt Issued | 226,900.00% | -100.01% | -- | -- | -- |
| Total Debt Repaid | 81.50% | 85.47% | -1,761.97% | 92.56% | -363.27% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -30.88% | -208.27% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -10.26% | 26.36% | -16.74% | 40.19% | 5.13% |
| Cash from Financing | 148.53% | -232.81% | 296.50% | 90.18% | -207.42% |
| Foreign Exchange rate Adjustments | 85.88% | -280.85% | 238.24% | -147.22% | -52.94% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 86.05% | -251.09% | 11,316.33% | 100.33% | -194.26% |